Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference By Investing.com
REDWOOD CITY, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) — Soleno Therapeutics (NASDAQ: ), Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel treatments for rare diseases, today announced that executives will present at the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024, at 8:00 AM Eastern Time.
A live audio webcast and replay of the presentation will be available in the investor section of the Company's website at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno focuses on the development and commercialization of novel therapies for the treatment of rare diseases. The NDA for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS) is currently under review by the FDA and has been granted Critical Review. For more information, please visit www.soleno.life.
Business Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
Source: Soleno Therapeutics
